Healthcare / Medical Care FacilitiesTokyo
$1151.00
-30.00 (-2.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-119.4M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
20.6x
↑EV/EBITDA
14.8x
↑ROE
2.4%
↑Gross Margin
66.3%
↑Debt/Equity
0.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
+29.3%
FCF margin
11.1%
FCF / Net income
9.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.53B · net income $17.2M · FCF $170.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.53B | $1.53B | $1.20B | $1.08B | $1.04B |
| Net Income | $17.2M | $17.2M | $-100.2M | $21.2M | $75.0M |
| EBITDA | $75.9M | $75.9M | $10.1M | $74.0M | $150.8M |
| EPS | 19.13 | 19.13 | -111.17 | 22.40 | 78.91 |
| Gross Margin | 66.3% | 66.3% | 64.1% | 72.4% | 67.7% |
| Operating Margin | 3.3% | 3.3% | -2.6% | 3.5% | 12.4% |
| Net Margin | 1.1% | 1.1% | -8.3% | 2.0% | 7.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.69 | 0.69 | 0.22 | 0.26 | 0.36 |
| Current Ratio | 1.56 | 1.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $170.3M | $170.3M | $-119.4M | $-119.5M | $78.8M |
| Returns | |||||
| ROE | 2.4% | 2.4% | -14.2% | 2.6% | 8.6% |
| Valuation | |||||
| P/E | 20.65 | 20.65 | — | 102.59 | 36.12 |
| EV/EBITDA | 14.82 | 14.82 | 153.30 | 22.57 | 13.15 |
| P/B | 1.47 | 1.47 | 2.46 | 2.70 | 3.11 |
| Growth & Yield | |||||
| Revenue Growth | 27.0% | 27.0% | 10.9% | 4.0% | — |
| EPS Growth | 117.2% | 117.2% | -596.3% | -71.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
74.8%
EPS terminal req.
$102.13
Spread vs growth
42.4%
5Y implied EPS CAGR
45.2%
EPS terminal req.
$123.58
Spread vs growth
72.0%
10Y implied EPS CAGR
26.4%
EPS terminal req.
$199.03
Spread vs growth
90.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-111.17 → 19.13
Residual
-28.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.